HM15275

HM15275 is Hanmi Pharmaceutical's investigational obesity peptide, now in Phase 2 in non-diabetic adults with overweight or obesity (NCT07205900, n=267, active not recruiting) [1] and a parallel Phase 2 in type 2 diabetes (NCT07527650, n=180, recruiting) [2]. The obesity study reads out the percent body weight change at 36 weeks - a head-to-head-able number against tirzepatide and semaglutide, which is the only relevant question this molecule has to answer. Hanmi has not publicly confirmed whether HM15275 is a mono-, dual-, or tri-agonist of the incretin receptors, which makes external valuation difficult and is itself a piece of information worth watching for. The interesting story here isn't really the molecule yet - it's whether Hanmi (KRX:128940, ~$4.3B market cap as of mid-2026 [9]) can finally produce a Korean-developed incretin asset that survives global partnership economics after Sanofi returned efpeglenatide in 2020 [10] and the Merck-partnered efinopegdutide was narrowed to MASH only after the obesity/T2D programs were dropped for tolerability [11].

Novel compound, never approved anywhere. Three trials on the books: a completed Phase 1 in healthy and obese subjects (NCT06481098, n=74) [3], the Phase 2 obesity study that has stopped enrolling at 267 patients [1], and a Phase 2 in type 2 diabetes that is still recruiting toward 180 patients [2]. No FDA designations are listed - no breakthrough, no fast track, no orphan, which is normal for an obesity asset competing in an established and well-served class. There is no public regulatory dialogue with FDA on file because the program is being run by a Korean sponsor at an early stage; this is not unusual. Expected readout for the obesity Phase 2 is plausibly late 2026 given a 36-week endpoint and an active-not-recruiting status, but Hanmi has not guided to a specific date in English-language disclosures I can verify. Treat that timing as inference, not company guidance. The diabetes study is much earlier and will not produce a meaningful HbA1c readout for at least 18 months. The audit on this node flagged mechanism_class as a placeholder; that is correct, and the gap reflects what Hanmi itself has chosen not to disclose. Composition-of-matter patent expiry is also unverified in English-language sources - flagged as missing.

Hanmi builds long-acting peptide drugs on a half-life extension platform they call LAPSCOVERY: the peptide is fused to a modified antibody fragment that the body recycles rather than clears, extending the drug's time in circulation from hours to a week or more and enabling once-weekly or longer dosing. The platform itself is real and validated - efpeglenatide (a GLP-1 agonist built on it) showed cardiovascular benefit in AMPLITUDE-O [4]. The unknown for HM15275 is which receptors it hits. GLP-1 and GIP are gut-derived hormones (the true incretins) that signal satiety to the brain and trigger appropriate insulin release from the pancreas; glucagon is a pancreatic hormone that raises blood glucose but, when targeted alongside GLP-1, also increases energy expenditure and accelerates fat loss. Semaglutide hits GLP-1 alone and gets you about 15% weight loss [5]; tirzepatide hits GLP-1 and GIP together and gets you about 22% [6]; the emerging triple agonists (retatrutide and others) hit all three for additive effect and look like they push higher. Where HM15275 sits on this spectrum is the central commercial question, and Hanmi has not said. The mechanism class is among the most genetically and clinically validated in modern pharmacology, so the binary risk on 'does the biology work' is low. The risk is 'is this molecule differentiated enough to matter'.

NCT07205900 is a Phase 2 in obese or overweight adults without diabetes, with percent change in body weight as the primary endpoint, n=267, active not recruiting [1]. A 36-week duration is reasonable for a weight-loss signal - semaglutide and tirzepatide both showed durable separation from placebo by week 28 - but it is shorter than the 68- and 72-week key trials and so will not capture the full plateau of weight loss. Whether there is an active comparator arm against semaglutide or tirzepatide is not clear from the registry entry; if it is placebo-controlled only, the readout will be informative for go/no-go but not for direct positioning against the incumbents. NCT07527650 is the diabetes Phase 2, primary endpoint HbA1c change (HbA1c is a blood test that captures average blood sugar over the prior three months), n=180, still recruiting [2]. Standard design for an incretin program. The most important thing about the design is what it does not include: no biomarker stratification, no genotype enrichment, no novel imaging endpoint. This is a straight-up efficacy trial that will live or die on the absolute weight-loss number, and that number needs to be in the conversation with tirzepatide to matter.

The model estimates a 6% chance this drug is eventually approved. It starts from the historical approval rate for Phase 2 drugs in this area (about 35%), then adjusts based on ten facts about the trial and sponsor. Larger-than-typical enrollment pushes the estimate up, while the sponsor's thin approval record, weak earlier-phase results, and heavier-than-usual blinding pull it down. The remaining factors are close to average for this stage and leave the number roughly where it started.

Efficacy risk is not 'does this mechanism work' - it almost certainly does - but 'is the number big enough'. The commercial bar for a new incretin in 2026 is roughly semaglutide's 15% at 68 weeks; below that, payers - the insurers and pharmacy benefit managers who decide what gets covered - will not put it on formulary over the incumbents. Safety risk is the standard incretin profile: nausea, vomiting, gallbladder events, and the recurring pancreatitis question that has followed the class for fifteen years. None of these have stopped approvals, but they shape the label. If HM15275 turns out to include glucagon agonism, there is added on-target risk around hepatic glucose output and blood pressure that needs careful tox monitoring - a relevant cautionary note given that the closely related Hanmi/Merck asset efinopegdutide (a GLP-1/glucagon dual agonist) was dropped from obesity and T2D development on tolerability and refocused to MASH only [11]. Execution risk is real: Hanmi has twice taken incretin assets to global partners with disappointing outcomes. Sanofi returned efpeglenatide in 2020 after five Phase 3 studies and ~6,000 patients [10]; the Merck deal on efinopegdutide (originally $10M upfront / up to $860M milestones in 2020 [8]) has shrunk to a single MASH indication with the program now slipping past its prior 2025 readout target [11]. Commercial risk is the dominant one. The injectable late-entrant playbook is also getting harder: Lilly's oral GLP-1 orforglipron hit its Phase 3 endpoints in 2025 with regulatory submissions filed for obesity in late 2025 and diabetes in 2026 [12], so by the time HM15275 could plausibly launch, the market will likely include a credible oral option that raises the patient-preference bar on injectables specifically. Partnership economics for Phase 2 obesity assets are anchored by Roche's December 2023 acquisition of Carmot Therapeutics for $2.7B upfront plus $400M milestones [13] - and that bought a Phase 2-ready dual GLP-1/GIP plus a Phase 1 oral plus a Phase 2 dual for T1D, not a single isolated Phase 2 peptide. A standalone Korean sponsor with one Phase 2 incretin and undisclosed mechanism is going to clear a smaller bar.

Watch, do not weight. The signal that matters is one number: percent body weight loss at 36 weeks in NCT07205900. Anything below 12% means Hanmi is selling this to an Asia-focused partner at a discount or quietly deprioritizing it. Between 12% and 18% it is a partnership candidate at modest economics - anchor expectations well below the Carmot/Roche $2.7B comp [13] given the single-asset, single-Phase-2, undisclosed-mechanism profile. Above 18% with clean tolerability and Hanmi gets a real auction, and the mechanism disclosure that comes with the readout will reset how the market values Hanmi's broader incretin platform. At ~$4.3B market cap [9], Hanmi already has meaningful pipeline value baked in - a clean obesity Phase 2 win could move the stock materially, while a 12-15% readout is roughly in line with expectations and unlikely to rerate it; below 12% would be punitive. Check back in late 2026 or whenever Hanmi confirms the obesity Phase 2 data drop - the active-not-recruiting status means the data exists or is about to. Until then, the more interesting thing to track is whether any disclosure comes out about which incretin receptors this molecule engages, because that single fact will tell you whether to map it onto the semaglutide curve, the tirzepatide curve, or the retatrutide-class curve. Also missing and worth pursuing: composition-of-matter patent expiry, Korean MFDS regulatory posture, and whether NCT07205900 has an active comparator arm - each materially changes the commercial framing. As a node in the obesity pipeline this is a B-tier asset by a B-tier global sponsor in an A-tier mechanism class. The mechanism class is what makes it worth keeping on the board at all.